Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 24, 2024

Durvalumab Immediately After Completion of Chemoradiotherapy in Patients With Unresectable Stage III NSCLC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study)
Clin. Cancer Res 2024 Jan 02;[EPub Ahead of Print], S Nakamichi, K Kubota, T Misumi, T Kondo, S Murakami, Y Shiraishi, H Imai, D Harada, K Isobe, H Itani, S Takata, H Wakui, Y Misumi, S Ikeda, T Asao, N Furuya, S Hosokawa, Y Kobayashi, Y Takiguchi, H Okamoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading